ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

January 18, 2008 12:53 ET

ART Time Domain Technology Applications to Be Presented at the Photonics West Conference in San Jose, California

Presentations highlight ongoing research for ART's SoftScan and Optix products

MONTREAL, CANADA--(Marketwire - Jan. 18, 2008) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be presenting five papers at the Photonics West/BiOS symposium, being held at the San Jose Convention Center in California, from January 19 to 24, 2008.

Scientific presentations featuring research based on ART's SoftScan® optical imaging device and the Optix® in vivo fluorescence optical imaging system include:

Oral Presentation Number: 6850-2. Fluorescence lifetime estimation of multiple near-infrared dyes in mice. Guobin Ma, Simon Fortier, Muriel Jean-Jacques, Niculae Mincu, Zahia Ichalalene, Frederic Leblond, Anader Benyamin-Seeyar, Mario Khayat, ART Advanced Research Technologies, Canada. Saturday, January 19, 2008, 9:10 am-9:30 am, Convention Center.

Oral Presentation Number: 6850-4. Characterization of natural fluorescence in mice. Salim Djeziri, Guobin Ma, Niculae Mincu, Anader Benyamin-Seeyar, ART Advanced Research Technologies, Canada. Saturday, January 19, 2008, 9:50 am-10:10 am, Convention Center.

Oral Presentation Number: 6850-12. Design and performance analysis of a small-animal fluorescence tomography system coupled to MicroCT. Dax S. Kepshire1, Michael Hutchins2, Annie Provencher2, Niculae Mincu2, Frederic Leblond2, Brian W. Pogue1, Mario Khayat2, 1Dartmouth College, 2ART Advanced Research Technologies, Canada. Saturday, January 19, 2008, 2:10 pm-2:30 pm, Convention Center.

Poster Presentation Number: 6854-62. Full path Monte-Carlo simulation of fluorescence in non-voxelized complex heterogeneous mouse model. Jean-Francois Delorme, Guobin Ma, Frederic Lesage, Frederic Leblond, Anader Benyamin-Seeyar, Mario Khayat, ART Advanced Research Technologies, Canada. Monday, January 21, 2008, 6:00 pm-7:30 pm, Civic Auditorium.

Oral Presentation Number: 6870-24. Diffuse optical tomography and spectroscopy performance assessment: phantoms and methodology. Niculae Mincu, Jean Brunette, Olga Guilman, Frederic Leblond, Salim Djeziri, Zahia Ichalalene, Guobin Ma, Mario Khayat, Anader Benyamin-Seeyar, ART Advanced Research Technologies, Canada. Sunday, January 20, 2008, 9:50 am-10:10 am, Convention Center.

Full texts of the abstracts can be obtained through the Photonics West/BiOS meeting program page (http://spie.org/x2595.xml) and following the link labeled "Search Program".

The Photonics West symposium, organized by the International Society of Optical Engineering, leads the way in the development and transfer of important light-enabled technologies, such as biomedical optics, and lasers and applications in science and engineering. For more information on this event, visit: http://spie.org/events/pw.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed directly by ART and is used by industry and academic leaders worldwide. The SoftScan® optical breast imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing the SoftScan optical medical imaging device via a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. The distribution of the Fenestra line of imaging contrast agents is made through GE Healthcare Bio-Science KK in Japan and is sold directly by the Company in the rest of the world. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).

Contact Information

  • ART Advanced Research Technologies Inc.
    Jacques Bedard
    Chief Financial Officer
    jbedard@art.ca
    or
    ART Advanced Research Technologies Inc.
    Mario Khayat
    Vice President, Optical Products
    514-832-0777
    mkhayat@art.ca
    www.art.ca